CTLA4 and melanoma: With respect to the checkpoint inhibitors, ipilimumab which targets T cell CTLA-4, was the first agent in this class to show an improved OS in melanoma, and meta-analysis of pooled data from ipilimumab trials which included 1861 melanoma patients revealed a 3-year OS rate of 22% [7, 8].